Zanubrutinib vs Ibrutinib in Symptomatic Waldenström Macroglobulinemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Randomized Phase 3 Trial of Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: The Aspen Study
Blood 2020 Jul 30;[EPub Ahead of Print], CS Tam, S Opat, S D'Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, BE Wahlin, R Garcia-Sanz, H McCarthy, S Mulligan, A Tedeschi, J Castillo, J Czyz, C Fernández de Larrea, D Belada, E Libby, JV Matous, M Motta, T Siddiqi, M Tani, M Trneny, MC Minnema, C Buske, V Leblond, WY Chan, JY Schneider, S Ro, A Cohen, J Huang, MA DimopoulosFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.